Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Khan Sharun, Kuldeep Dhama, Shailesh Kumar Patel, Mamta Pathak, Ruchi Tiwari, Bhoj Raj Singh, Ranjit Sah, D Katterine Bonilla-Aldana, Alfonso J Rodriguez-Morales, Hakan Leblebicioglu, Khan Sharun, Kuldeep Dhama, Shailesh Kumar Patel, Mamta Pathak, Ruchi Tiwari, Bhoj Raj Singh, Ranjit Sah, D Katterine Bonilla-Aldana, Alfonso J Rodriguez-Morales, Hakan Leblebicioglu

No abstract available

Keywords: 2019-nCoV; COVID-19; Coronavirus; Ivermectin; SARS-CoV-2; Therapeutics.

Conflict of interest statement

None.

Figures

Fig. 1
Fig. 1
Chemical structure of ivermectin, the 22, 23-dihydro derivative of a macrocyclic lactone avermectin B1
Fig. 2
Fig. 2
Potential modes of anti-viral actions of ivermectin

References

    1. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 doi: 10.1016/j.antiviral.2020.104787.
    1. Campbell WC, Benz GW. Ivermectin: a review of efficacy and safety. J Vet Pharmacol Ther. 1984;7(1):1–16. doi: 10.1111/j.1365-2885.1984.tb00872.x.
    1. Crump A, Omura S. Ivermectin, ‘wonderdrug’ from Japan: the human use perspective. Proceed Japan Acad Series B. 2011;87(2):13–28. doi: 10.2183/pjab.87.13.
    1. Sharun K, Shyamkumar TS, Aneesha VA, Dhama K, Pawde AM, Pal A. Current therapeutic applications and pharmacokinetic modulations of ivermectin. Vet World. 2019;12(8):1204–1211. doi: 10.14202/vetworld.2019.1204-1211.
    1. Rang HP, Dale MM, Ritter JM, Flower RJ, editors. Rang and Dale’s Pharmacology. 6. China: Churchill Livingstone; 2007. pp. 715–716.
    1. Nguyen KY, Sakuna K, Kinobe R, Owens L. Ivermectin blocks the nuclear location signal of parvoviruses in crayfish, Cherax quadricarinatus. Aquaculture. 2014;420–421:288–294. doi: 10.1016/j.aquaculture.2013.11.022.
    1. Barrows NJ, Campos RK, Powell ST, Prasanth KR, Schott-Lerner G, Soto-Acosta R, Galarza-Muñoz G, McGrath EL, Urrabaz-Garza R, Gao J, Wu P, Menon R, Saade G, Fernandez-Salas I, Rossi SL, Vasilakis N, Routh A, Bradrick SS, Garcia-Blanco MA. A screen of FDA-approved drugs for inhibitors of zika virus infection. Cell Host Microbe. 2016;20(2):259–270. doi: 10.1016/j.chom.2016.07.004.
    1. Götz V, Magar L, Dornfeld D, Giese S, Pohlmann A, Höper D, Kong BW, Jans DA, Beer M, Haller O, Schwemmle M. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep. 2016;18(6):23138. doi: 10.1038/srep23138.
    1. Lundberg L, Pinkham C, Baer A, Amaya M, Narayanan A, Wagstaff KM, Jans DA, Kehn-Hall K. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis virus replication. Antiviral Res. 2013;100(3):662–672. doi: 10.1016/j.antiviral.2013.10.004.
    1. Nguyen C, Burton T, Kuklinski W, Gray M, Foy BD. Ivermectin for the control of west nile virus transmission. New Horizons Transl Med. 2015;2(4):127. doi: 10.1016/j.nhtm.2015.07.043.
    1. Lee YJ, Lee C. Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. Arch Virol. 2016;161(2):257–268. doi: 10.1007/s00705-015-2653-2.
    1. Azeem S, Ashraf M, Rasheed MA, Anjum AA, Hameed R. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak J Pharm Sci. 2015;28(2):597–602.
    1. Varghese FS, Kaukinen P, Gläsker S, Bespalov M, Hanski L, Wennerberg K, Kümmerer BM, Ahola T. Discovery of berberine, abamectin, and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Res. 2016;126:117–124. doi: 10.1016/j.antiviral.2015.12.012.
    1. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit the replication of HIV-1 and dengue virus. Biochem J. 2012;443(3):851–856. doi: 10.1042/BJ20120150.
    1. Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K, de Lamballerie X, Neyts J, Hanson AM, Frick DN, Bolognesi M, Milani M. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother. 2012;67(8):1884–1894. doi: 10.1093/jac/dks147.
    1. Lv C, Liu W, Wang B, Dang R, Qiu L, Ren J, Yan C, Yang Z, Wang X. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res. 2018;159:55–62. doi: 10.1016/j.antiviral.2018.09.010.
    1. Wang X, Lv C, Ji X, Wang B, Qiu L, Yang Z. Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets. Virus Res. 2019;2(263):80–86. doi: 10.1016/j.virusres.2019.01.010.
    1. Raza S, Shahin F, Zhai W, Li H, Alvisi G, Yang K, Chen X, Chen Y, Chen J, Hu C, Chen H, Guo A. Ivermectin inhibits bovine herpesvirus 1 DNA polymerase nuclear import and interferes with viral replication. Microorganisms. 2020;8(3):E409. doi: 10.3390/microorganisms8030409.
    1. Ketkar H, Yang L, Wormser GP, Wang P. Lack of the efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diagn Microbiol Infect Dis. 2019;95(1):38–40. doi: 10.1016/j.diagmicrobio.2019.03.012.
    1. Crump A. Ivermectin: enigmatic multifaceted ‘wonder’ drug continues to surprise and exceed expectations. J Antibiot. 2017;70(5):495–505. doi: 10.1038/ja.2017.11.
    1. Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, Jans DA. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res. 2020;2:104760. doi: 10.1016/j.antiviral.2020.104760.
    1. Patrì A, Fabbrocini G. Hydroxychloroquine and ivermectin: a synergisticcombination for COVID-19 chemoprophylaxis and/or treatment? J Am Acad Dermatol. 2020 doi: 10.1016/j.jaad.2020.04.017.
    1. Patel A, Desai S. Ivermectin in COVID-19 Related critical illness. SSRN. 2020 doi: 10.2139/ssrn.3570270.
    1. Millan-Oñate J, Millan W, Mendoza LA, Sánchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, Rodriguez-Morales AJ. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann Clin Microbiol Antimicrob. 2020 doi: 10.1186/s12941-020-00358.
    1. Croci R, Bottaro E, Chan KW, Watanabe S, Pezzullo M, Mastrangelo E, Nastruzzi C. Liposomal systems as nanocarriers for the antiviral agent ivermectin. Int J Biomater. 2016;2016:8043983. doi: 10.1155/2016/8043983.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner